Table 2.

Association between exposure to aspirin and COVID-19 (groups 1 and 2).

	Case patients (%)	Control patients (%)	Unadjusted OR (95% CI)	Adjusted OR (95% CI)	Adjusted OR (95% CI)
Group 1
PSM 1	3825 (100)	7650 (100)		Model 1∗	Model 2†
Non-exposure to aspirin	3512 (91.8)	7119 (93.1)	1.00	1.00	1.00
Exposure to aspirin	313 (8.2)	531 (6.9)	1.21 (1.04–1.41)	1.08 (0.92–1.27)	1.11 (0.94–1.30)
PSM 2	3825 (100)	7650 (100)		Model 3‡
Non-exposure to aspirin	3512 (91.8)	7033 (91.9)	1.00	1.00
Exposure to aspirin	313 (8.2)	617 (8.1)	1.20 (0.87–1.20)	1.02 (0.87–1.21)
PSM 3	128 (100)	128 (100)
Non-exposure to aspirin	3512 (91.8)	7042 (92.1)	1.00
Exposure to aspirin	313 (8.2)	608 (7.9)	1.03 (0.90–1.19)

Group 2
PSM 1	7223 (100)	14,446 (100)		Model 1∗
Non-exposure to aspirin	6792 (94.0)	13,694 (94.8)	1.00	1.00
Exposure to aspirin	431 (6.0)	752 (5.2)	1.18 (1.03–1.34)	1.01 (0.88–1.16)
PSM 2	7222 (100)	14,443 (100)
Non-exposure to aspirin	6792 (94.1)	13,568 (93.9)	1.00
Exposure to aspirin	430 (5.9)	875 (6.1)	0.98 (0.85–1.12)